ArticleHeliyon2024
Osteonecrosis of the jaw associated with ustekinumab in the treatment of Crohn's.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MRONJ is a well-known side effect of antiresorptive and antiangiogenic drug treatment. Crohn's disease involves pro-inflammatory interleukins IL-12 and IL-23. Ustekinumab is a targeted therapy antagonist of the p40 subunit of IL-12 and -23 indicated in the treatment of immune-mediated inflammatory diseases. A 72-year-old man with Crohn's disease developed MRONJ after being treated with ustekinumab for four years. The patient presented with bone exposure three months after the extraction of two mandibular teeth. He had no known predisposing factors and never received ARDs. The patient underwent surgical treatment, and ustekinumab treatment was suspended for six months. No recurrence of MRONJ was detected after 12 months. Although the new definition of MRONJ excludes antiangiogenic molecules, tyrosine kinase inhibitors, and mTOR inhibitors alone, some cases have been reported with ustekinumab. This report highlights the possibility of MRONJ occurring when taking ustekinumab for Crohn's disease, even without being treated with antiresorptive drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.